Dr. D. K. Brahma
Associate Professor
Department of Pharmacology
NEIGRIHMS, Shillong
 Demographic transition – a global
demographic event
 WHO – People 60 years of age and older is
650 million now and forecast to reach 2 Billion
by 2050
 Persons aged 65 years and older constitute
13% of the population and purchase 33% of
all prescription medications
 By 2040, 25% of the population will purchase
50% of all prescription drugs
 Medications play crucial role in geriatric health
care as they treat chronic diseases, alleviate pain
and improve quality of life
 Age-related changes in drug disposition and
pharmacodynamic responses have significant
clinical implications
 Increased use of a number of medications in
elderly raises the risk of medicine-related problems
that may occur
 Medication use and the incidence of adverse drug
outcomes increase with advancing age
 It is important to ensure quality use of medicines in
older people
 Large number of new drugs available each
year
 Off-label indications are expanding
 Advanced understanding of drug-drug
interactions
 Increasing popularity of “nutriceuticals”
 Multiple co-morbid states
 Polypharmacy
 Medication compliance
 Effects of aging physiology on drug therapy
 Medication cost
Rate of absorption may be delayed
• Lower peak concentration
• Delayed time to peak concentration
Factors:
• Increased GI pH
• Decreased gastric emptying
• Dysphagia
• Route of administration
• Co-morbidity conditions
• Presence of drugs (pH and gastric emptying) and
additives
Aging Effect Vd Effect Examples
 body water  Vd for hydrophilic
drugs
ethanol, lithium
 lean body mass  Vd for drugs that
bind to muscle
digoxin
 fat stores  Vd for lipophilic
drugs
diazepam, trazodone
 plasma protein
(albumin)
 % of unbound or
free drug (active)
diazepam, valproic acid,
phenytoin, warfarin
Reduced amount of water in the body - fat soluble drugs remain longer in
the body with prolonged effects – of importance for some sedatives and
anxiolytics
Pathway Effect Examples
Phase I:
oxidation,
hydroxylation,
dealkylation,
reduction
Conversion
to
metabolites
of lesser,
equal, or
greater
diazepam,
quinidine,
piroxicam,
theophylline
Phase II:
glucuronidatio,
conjugation, or
acetylation
Conversion
to inactive
metabolites
lorazepam,
oxazepam,
temazepam
•Reduced liver function
•Hepatic microsomal
drug metabolizing activity
may be reduced due to:
decreased hepatic
blood flow
decreased liver size
and mass
Examples: morphine,
metoprolol, propranolol,
verapamil, amitryptyline,
nortriptyline (sensitivity to
beta-blockers reduced)
 Reduced kidney function - decreased excretion of
some cardiovascular drugs, some antibiotics,
diabetic drugs, antiinflammatory drugs – need to
reduce dosage
 Decreased kidney size
 Decreased renal blood flow
 Decreased number of functional nephrons
 Decreased tubular secretion
 Result:  glomerular filtration rate (GFR)
 Decreased drug clearance: atenolol, gabapentin,
H2 blockers, digoxin, allopurinol, quinolones
 Creatinine clearance (CrCl) is used to estimate
glomerular rate
Brain and nervous system more sensitive
to psychotropic and analgesic drugs –
dizziness, confusion, cognitive impairment
Decreased capacity to regulate blood
pressure – blood pressure fall, fainting,
vertigo when using drugs for hypertension
Gastrointestinal sensitivity to anti-
inflammatory drugs - bleeding
Balance between overprescribing and
underprescribing
• Correct drug
• Correct dose
• Targets appropriate condition
• Is appropriate for the individual patient
Avoid “a pill for every ill”
Always consider non-pharmacologic therapy
Adverse drug events (ADEs)
Drug interactions
Duplication of drug therapy
Decreased quality of life
Unnecessary cost
Medication non-adherence
 Responsible for 5-28% of acute geriatric hospital
admissions
 Greater than 95% of ADEs in the elderly are
considered predictable (Type A) and approximately
50% are considered preventable
 Most errors occur at the ordering and monitoring
stages
 Most common medications associated with ADEs
in elderly
• Opioid analgesics
• NSAIDs
• Anticholinergics
• Benzodiazepines
• Also: cardiovascular agents, CNS agents, and
musculoskeletal agents
High potential to cause severe ADEs in
elderly – amitriptyline, chlorpropamide,
digoxin >0.125mg/d, disopyramide,
antispasmodics, meperidine, methyldopa,
pentazocine, ticlopidine
High potential but less severe:
antihistamines, diphenhydramine,
dipyridamole, ergot mesyloids,
indomethacin, muscle relaxants
ADE interpreted as new
medical condition
Drug 1
Drug 2
ADE interpreted as new
medical condition
Drug 3
Rochon PA, Gurwitz JH. Optimizing drug treatment in elderly people: the prescribing cascase. BMJ 1997;315:1097.
Combination Risk
ACE inhibitor + potassium Hyperkalemia
ACE inhibitor + K sparing diuretic Hyperkalemia, hypotension
Digoxin + antiarrhythmic Bradycardia, arrhythmia
Digoxin + diuretic
Antiarrhythmic + diuretic
Electrolyte imbalance; arrhythmia
Diuretic + diuretic Electrolyte imbalance; dehydration
Benzodiazepine + antidepressant
Benzodiazepine + antipsychotic
Sedation; confusion; falls
CCB/nitrate/vasodilator/diuretic Hypotension
Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a
prospective study of 1000 patients. J Am Geriatr Soc 1996;44(9):944-948.
Combination Risk
NSAIDs + CHF
Thiazolidinediones + CHF
Fluid retention; CHF exacerbation
BPH + anticholinergics Urinary retention
CCB + constipation
Narcotics + constipation
Anticholinergics + constipation
Exacerbation of constipation
Metformin + CHF Hypoxia; increased risk of lactic
acidosis
NSAIDs + gastropathy Increased ulcer and bleeding risk
NSAIDs + HTN Fluid retention; decreased
effectiveness of diuretics
1. When meeting the patient - get ready to spent more time and understand the
patient and his problems – see the whole patient as a part of whole
2. Identify the patient`s need of treatment – diagnosis important - Have a
comprehensive view
3. Symptoms can be adverse reactions to drugs
4. Record which other drugs the patient is using
5. Evaluate what has to be prescribed – make a benefit risk assessment, is there any
medication which should be stopped – must avoid Polypharmacy
6. Which dosage and administration form is appropriate
7. Make a plan for the treatment, when to meet for a follow-up of the effects of the
treatment and discuss this with the patient or her or his carer
• Use of lower doses, longer intervals, slower titration are helpful in decreasing the
risk of drug intolerance and toxicity
8. Careful monitoring is necessary to ensure successful outcomes
9. Remember:
• Balance between under prescribing and overprescribing
• Avoid “a pill for every ill”
• Always consider non-pharmacologic therapy
10. Report adverse reactions if they occur
Always take utmost care and responsibility
while prescribing medicines to an aged
patient – think, re-think, discuss with
colleague/seniors - if needed and apply
your best intellectual knowledge - Be
cautious with NSAIDS, CNS drugs, CVS
drugs, diuretics and oral hypoglycaemics
Brahma DK, Wahlang JB, Marak MD, Ch. Sangma M. Adverse drug reactions in the elderly. J Pharmacol Pharmacother [serial online] 2013 [cited 2017 Sep 24];4:91-4.
Available from: http://www.jpharmacol.com/text.asp?2013/4/2/91/110872
We do not want to meet ageism
We do not want to be discriminated
We want to keep our self-determination
We want to keep our dignity, integrity
We want to feel we are a resource
When in need, we want access to high
quality care and services including
palliative care
At the very end of life we should not
Barbro Westerholm.Prof.em, Member of Swedish Parliament. EFNS Stockholm 2012; Presentation - Healthy ageing and medicines - European Medicines
...www.ema.europa.eu/docs/en_GB/document_library/.../2012/.../WC500125120.pdf
“To care for those who once
cared for us is one of the
highest honours.”

Medications in the elderly

  • 1.
    Dr. D. K.Brahma Associate Professor Department of Pharmacology NEIGRIHMS, Shillong
  • 2.
     Demographic transition– a global demographic event  WHO – People 60 years of age and older is 650 million now and forecast to reach 2 Billion by 2050  Persons aged 65 years and older constitute 13% of the population and purchase 33% of all prescription medications  By 2040, 25% of the population will purchase 50% of all prescription drugs
  • 3.
     Medications playcrucial role in geriatric health care as they treat chronic diseases, alleviate pain and improve quality of life  Age-related changes in drug disposition and pharmacodynamic responses have significant clinical implications  Increased use of a number of medications in elderly raises the risk of medicine-related problems that may occur  Medication use and the incidence of adverse drug outcomes increase with advancing age  It is important to ensure quality use of medicines in older people
  • 4.
     Large numberof new drugs available each year  Off-label indications are expanding  Advanced understanding of drug-drug interactions  Increasing popularity of “nutriceuticals”  Multiple co-morbid states  Polypharmacy  Medication compliance  Effects of aging physiology on drug therapy  Medication cost
  • 5.
    Rate of absorptionmay be delayed • Lower peak concentration • Delayed time to peak concentration Factors: • Increased GI pH • Decreased gastric emptying • Dysphagia • Route of administration • Co-morbidity conditions • Presence of drugs (pH and gastric emptying) and additives
  • 6.
    Aging Effect VdEffect Examples  body water  Vd for hydrophilic drugs ethanol, lithium  lean body mass  Vd for drugs that bind to muscle digoxin  fat stores  Vd for lipophilic drugs diazepam, trazodone  plasma protein (albumin)  % of unbound or free drug (active) diazepam, valproic acid, phenytoin, warfarin Reduced amount of water in the body - fat soluble drugs remain longer in the body with prolonged effects – of importance for some sedatives and anxiolytics
  • 7.
    Pathway Effect Examples PhaseI: oxidation, hydroxylation, dealkylation, reduction Conversion to metabolites of lesser, equal, or greater diazepam, quinidine, piroxicam, theophylline Phase II: glucuronidatio, conjugation, or acetylation Conversion to inactive metabolites lorazepam, oxazepam, temazepam •Reduced liver function •Hepatic microsomal drug metabolizing activity may be reduced due to: decreased hepatic blood flow decreased liver size and mass Examples: morphine, metoprolol, propranolol, verapamil, amitryptyline, nortriptyline (sensitivity to beta-blockers reduced)
  • 8.
     Reduced kidneyfunction - decreased excretion of some cardiovascular drugs, some antibiotics, diabetic drugs, antiinflammatory drugs – need to reduce dosage  Decreased kidney size  Decreased renal blood flow  Decreased number of functional nephrons  Decreased tubular secretion  Result:  glomerular filtration rate (GFR)  Decreased drug clearance: atenolol, gabapentin, H2 blockers, digoxin, allopurinol, quinolones  Creatinine clearance (CrCl) is used to estimate glomerular rate
  • 9.
    Brain and nervoussystem more sensitive to psychotropic and analgesic drugs – dizziness, confusion, cognitive impairment Decreased capacity to regulate blood pressure – blood pressure fall, fainting, vertigo when using drugs for hypertension Gastrointestinal sensitivity to anti- inflammatory drugs - bleeding
  • 10.
    Balance between overprescribingand underprescribing • Correct drug • Correct dose • Targets appropriate condition • Is appropriate for the individual patient Avoid “a pill for every ill” Always consider non-pharmacologic therapy
  • 11.
    Adverse drug events(ADEs) Drug interactions Duplication of drug therapy Decreased quality of life Unnecessary cost Medication non-adherence
  • 12.
     Responsible for5-28% of acute geriatric hospital admissions  Greater than 95% of ADEs in the elderly are considered predictable (Type A) and approximately 50% are considered preventable  Most errors occur at the ordering and monitoring stages  Most common medications associated with ADEs in elderly • Opioid analgesics • NSAIDs • Anticholinergics • Benzodiazepines • Also: cardiovascular agents, CNS agents, and musculoskeletal agents
  • 13.
    High potential tocause severe ADEs in elderly – amitriptyline, chlorpropamide, digoxin >0.125mg/d, disopyramide, antispasmodics, meperidine, methyldopa, pentazocine, ticlopidine High potential but less severe: antihistamines, diphenhydramine, dipyridamole, ergot mesyloids, indomethacin, muscle relaxants
  • 14.
    ADE interpreted asnew medical condition Drug 1 Drug 2 ADE interpreted as new medical condition Drug 3 Rochon PA, Gurwitz JH. Optimizing drug treatment in elderly people: the prescribing cascase. BMJ 1997;315:1097.
  • 15.
    Combination Risk ACE inhibitor+ potassium Hyperkalemia ACE inhibitor + K sparing diuretic Hyperkalemia, hypotension Digoxin + antiarrhythmic Bradycardia, arrhythmia Digoxin + diuretic Antiarrhythmic + diuretic Electrolyte imbalance; arrhythmia Diuretic + diuretic Electrolyte imbalance; dehydration Benzodiazepine + antidepressant Benzodiazepine + antipsychotic Sedation; confusion; falls CCB/nitrate/vasodilator/diuretic Hypotension Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 1996;44(9):944-948.
  • 16.
    Combination Risk NSAIDs +CHF Thiazolidinediones + CHF Fluid retention; CHF exacerbation BPH + anticholinergics Urinary retention CCB + constipation Narcotics + constipation Anticholinergics + constipation Exacerbation of constipation Metformin + CHF Hypoxia; increased risk of lactic acidosis NSAIDs + gastropathy Increased ulcer and bleeding risk NSAIDs + HTN Fluid retention; decreased effectiveness of diuretics
  • 17.
    1. When meetingthe patient - get ready to spent more time and understand the patient and his problems – see the whole patient as a part of whole 2. Identify the patient`s need of treatment – diagnosis important - Have a comprehensive view 3. Symptoms can be adverse reactions to drugs 4. Record which other drugs the patient is using 5. Evaluate what has to be prescribed – make a benefit risk assessment, is there any medication which should be stopped – must avoid Polypharmacy 6. Which dosage and administration form is appropriate 7. Make a plan for the treatment, when to meet for a follow-up of the effects of the treatment and discuss this with the patient or her or his carer • Use of lower doses, longer intervals, slower titration are helpful in decreasing the risk of drug intolerance and toxicity 8. Careful monitoring is necessary to ensure successful outcomes 9. Remember: • Balance between under prescribing and overprescribing • Avoid “a pill for every ill” • Always consider non-pharmacologic therapy 10. Report adverse reactions if they occur
  • 18.
    Always take utmostcare and responsibility while prescribing medicines to an aged patient – think, re-think, discuss with colleague/seniors - if needed and apply your best intellectual knowledge - Be cautious with NSAIDS, CNS drugs, CVS drugs, diuretics and oral hypoglycaemics
  • 19.
    Brahma DK, WahlangJB, Marak MD, Ch. Sangma M. Adverse drug reactions in the elderly. J Pharmacol Pharmacother [serial online] 2013 [cited 2017 Sep 24];4:91-4. Available from: http://www.jpharmacol.com/text.asp?2013/4/2/91/110872
  • 20.
    We do notwant to meet ageism We do not want to be discriminated We want to keep our self-determination We want to keep our dignity, integrity We want to feel we are a resource When in need, we want access to high quality care and services including palliative care At the very end of life we should not Barbro Westerholm.Prof.em, Member of Swedish Parliament. EFNS Stockholm 2012; Presentation - Healthy ageing and medicines - European Medicines ...www.ema.europa.eu/docs/en_GB/document_library/.../2012/.../WC500125120.pdf
  • 21.
    “To care forthose who once cared for us is one of the highest honours.”